Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AUNG NAING

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1104837590
CMS profile
366226
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,639.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Incyte Corporation $2,639.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AUNG NAING

NPI 1104837590 · CMS profile ID 366226

Allopathic & Osteopathic Physicians / Internal Medicine

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1104837590?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AUNG NAING, NPI 1104837590, CMS profile ID 366226. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104837590?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). AUNG NAING, NPI 1104837590, CMS profile ID 366226. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104837590?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
AUNG NAING, NPI 1104837590, CMS profile ID 366226, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1104837590?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $2,639.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Incyte Corporation $2,639.0004/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835545359 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,309.43 16
PY2020 $211.34 1
PY2021 $2,639.00 1
PY2022 $5,205.00 2
PY2023 $3,375.00 2
PY2025 $4,703.88 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,918,481.53 469
PY2024 Recipient $4,531.10 4
PY2024 Principal investigator $4,445,667.71 159
PY2023 Principal investigator $4,761,955.67 97
PY2022 Principal investigator $3,708,621.77 334
PY2021 Principal investigator $5,802,399.26 154
PY2020 Recipient $2,459.66 4
PY2020 Principal investigator $1,927,221.68 148
PY2019 Principal investigator $5,972,979.75 356

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

152 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $252.90 12/22/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744296557
Principal investigator 1 Incyte Corporation $1,181.70 12/22/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744296561
Principal investigator 1 Incyte Corporation $5,166.00 12/22/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744296563
Principal investigator 1 Incyte Corporation $9,191.70 12/22/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744296565
Principal investigator 1 Incyte Corporation $7,901.10 12/22/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744296567
Principal investigator 1 Incyte Corporation $3,750.00 12/22/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, 2, Open Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors, ECHO 207/KEYNOTE 723 No dispute reported 06/30/2026 744296569
Principal investigator 1 Incyte Corporation $780.00 12/22/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, 2, Open Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors, ECHO 207/KEYNOTE 723 No dispute reported 06/30/2026 744296571
Principal investigator 1 Incyte Corporation $474.00 12/22/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, 2, Open Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors, ECHO 207/KEYNOTE 723 No dispute reported 06/30/2026 744296573
Principal investigator 1 Incyte Corporation $68,273.00 12/22/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, 2, Open Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors, ECHO 207/KEYNOTE 723 No dispute reported 06/30/2026 744296575
Principal investigator 1 Incyte Corporation $3,240.00 12/22/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, 2, Open Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors, ECHO 207/KEYNOTE 723 No dispute reported 06/30/2026 744296577
Principal investigator 1 Incyte Corporation $2,500.00 12/22/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, 2, Open Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors, ECHO 207/KEYNOTE 723 No dispute reported 06/30/2026 744296579
Principal investigator 1 Incyte Corporation $86.00 12/22/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, 2, Open Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors, ECHO 207/KEYNOTE 723 No dispute reported 06/30/2026 744296581
Principal investigator 1 Incyte Corporation $6,963.84 12/10/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, 2, Open Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors, ECHO 207/KEYNOTE 723 No dispute reported 06/30/2026 744296525
Principal investigator 1 Incyte Corporation $5,000.00 12/10/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, 2, Open Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors, ECHO 207/KEYNOTE 723 No dispute reported 06/30/2026 744296527
Principal investigator 1 Incyte Corporation $16,206.00 12/10/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, 2, Open Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors, ECHO 207/KEYNOTE 723 No dispute reported 06/30/2026 744296529
Principal investigator 1 Incyte Corporation $820.00 12/10/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, 2, Open Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors, ECHO 207/KEYNOTE 723 No dispute reported 06/30/2026 744296531
Principal investigator 1 Incyte Corporation $3,750.00 12/10/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, 2, Open Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors, ECHO 207/KEYNOTE 723 No dispute reported 06/30/2026 744296533
Principal investigator 1 Incyte Corporation $374.00 12/10/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, 2, Open Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors, ECHO 207/KEYNOTE 723 No dispute reported 06/30/2026 744296535
Principal investigator 1 Incyte Corporation $1,700.00 12/10/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, 2, Open Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors, ECHO 207/KEYNOTE 723 No dispute reported 06/30/2026 744296537
Principal investigator 1 Eli Lilly and Company $2,480.97 11/09/2020 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PEGILODECAKIN (LY3500518) IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 728729167
Principal investigator 1 Incyte Corporation $105.48 11/09/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744309565
Principal investigator 1 Incyte Corporation $95.00 11/01/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744296165
Principal investigator 1 EMD Serono, Inc. $17,035.20 10/13/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase I, First-in-Human, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of M6223 (an Inhibitor of TIGIT) as Single Agent and in Combination with Bintrafusp Alfa (anti-PDL1/ TGF Trap in Participants with Metastatic or Locally Advanced Solid Unresectable Tumors No dispute reported 06/30/2026 749617781
Principal investigator 1 Incyte Corporation $95.00 10/01/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744296169
Principal investigator 1 Incyte Corporation $1,371.00 09/23/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744296455
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,781.25 09/18/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase IIB TMB High Pan Tumor FA for tTMB No dispute reported 06/30/2026 736755881
Principal investigator 1 EMD Serono, Inc. $1,802.00 09/18/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749609723
Principal investigator 1 EMD Serono, Inc. $1,802.00 09/18/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749609725
Principal investigator 1 EMD Serono, Inc. $1,802.00 09/18/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749609727
Principal investigator 1 Novartis Pharmaceuticals Corporation $96,616.88 09/15/2020 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE IB II OPEN LABEL MULTICENTER STUDY OF MCS110 IN COMBINATION WITH PDR001 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 721488937
Recipient Regeneron Pharmaceuticals, Inc. $868.37 09/09/2020 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 724434937
Principal investigator 1 Incyte Corporation $111,689.68 09/02/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers No dispute reported 06/30/2026 744278385
Principal investigator 1 Incyte Corporation $95.00 09/01/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744296161
Principal investigator 1 EMD Serono, Inc. $61.00 08/31/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749587151
Principal investigator 1 Incyte Corporation $16,194.80 08/27/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744296431
Principal investigator 1 Incyte Corporation $7,862.40 08/27/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744296433
Principal investigator 1 Merck Sharp & Dohme Corporation $162,500.00 08/26/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open-label Phase 1b,2a Study of NT-I7 Hyleukin-7 in Combination with Pembrolizumab in Subjects with Relapsed,Refractory Advanced Solid Tumors No dispute reported 06/30/2026 740816865
Principal investigator 1 Incyte Corporation $23,608.80 08/20/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744296429
Principal investigator 1 Incyte Corporation $95.00 08/01/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744296157
Principal investigator 1 EMD Serono, Inc. $61.00 07/31/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749587173
Principal investigator 1 Incyte Corporation $162.72 07/09/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308873
Principal investigator 1 Incyte Corporation $329.45 07/09/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308875
Principal investigator 1 Incyte Corporation $38.70 07/09/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308877
Principal investigator 1 Incyte Corporation $28.16 07/09/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308879
Principal investigator 1 Incyte Corporation $96.96 07/09/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308881
Principal investigator 1 Incyte Corporation $508.32 07/09/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308883
Principal investigator 1 Incyte Corporation $175.80 07/09/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308885
Principal investigator 1 Incyte Corporation $123.68 07/09/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308887
Principal investigator 1 Incyte Corporation $7.10 07/09/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308889
Principal investigator 1 Incyte Corporation $93.60 07/09/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308891
Principal investigator 1 Incyte Corporation $76.40 07/09/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308893
Principal investigator 1 Incyte Corporation $188.00 07/09/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308895
Principal investigator 1 Incyte Corporation $93.60 07/09/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308903
Principal investigator 1 Incyte Corporation $93.60 07/09/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308905
Principal investigator 1 Incyte Corporation $93.60 07/09/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308907
Principal investigator 1 Incyte Corporation $188.00 07/09/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308909
Principal investigator 1 Incyte Corporation $76.40 07/09/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308911
Principal investigator 1 Incyte Corporation $188.00 07/09/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308913
Principal investigator 1 Incyte Corporation $76.40 07/09/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308915
Principal investigator 1 Merck Sharp & Dohme Corporation $364,653.00 07/09/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase II Study for the Evaluation of Efficacy of Pembrolizumab MK-3475 in Patients with Advanced Types of Cancers No dispute reported 06/30/2026 740819783
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $46,178.05 07/02/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open Label Phase 2 Multicohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CheckMate 627) No dispute reported 06/30/2026 736755967
Principal investigator 1 Incyte Corporation $95.00 07/01/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744296145
Principal investigator 1 EMD Serono, Inc. $61.00 06/30/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749587135
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,194.00 06/22/2020 Non-covered Recipient Entity
UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
A PHASE I AND OR II OPEN LABEL MULTI CENTER STUDY OF THE SAFETY AND EFFICACY OF BLZ945 AS SINGLE AGENT AND IN COMBINATION WITH PDR001 IN ADULTS PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 721497221
Principal investigator 1 Eli Lilly and Company $4,769.00 06/08/2020 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH
A PHASE 1 STUDY OF PEGILODECAKIN (LY3500518) IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 728753163
Principal investigator 1 Incyte Corporation $95.00 06/01/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744296133
Principal investigator 1 EMD Serono, Inc. $61.00 05/29/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749587071
Principal investigator 1 Merck Sharp & Dohme Corporation $65,000.00 05/29/2020 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open-label Phase 1b,2a Study of NT-I7 Hyleukin-7 in Combination with Pembrolizumab in Subjects with Relapsed,Refractory Advanced Solid Tumors No dispute reported 06/30/2026 740826959
Principal investigator 1 Incyte Corporation $70.50 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308739
Principal investigator 1 Incyte Corporation $58.50 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308741
Principal investigator 1 Incyte Corporation $35.10 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308743
Principal investigator 1 Incyte Corporation $24.24 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308747
Principal investigator 1 Incyte Corporation $76.40 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308749
Principal investigator 1 Incyte Corporation $28.65 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308751
Principal investigator 1 Incyte Corporation $117.50 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308753
Principal investigator 1 Incyte Corporation $5.04 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308755
Principal investigator 1 Incyte Corporation $57.30 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308757
Principal investigator 1 Incyte Corporation $7.04 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308759
Principal investigator 1 Incyte Corporation $137.67 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308761
Principal investigator 1 Incyte Corporation $70.32 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308763
Principal investigator 1 Incyte Corporation $92.76 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308765
Principal investigator 1 Incyte Corporation $93.60 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308767
Principal investigator 1 Incyte Corporation $9.92 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308769
Principal investigator 1 Incyte Corporation $105.48 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308771
Principal investigator 1 Incyte Corporation $38.70 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308773
Principal investigator 1 Incyte Corporation $2.56 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308775
Principal investigator 1 Incyte Corporation $508.32 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308777
Principal investigator 1 Incyte Corporation $162.72 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308779
Principal investigator 1 Incyte Corporation $7.10 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308781
Principal investigator 1 Incyte Corporation $188.00 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308783
Principal investigator 1 Incyte Corporation $96.96 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308785
Principal investigator 1 Incyte Corporation $76.78 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308787
Principal investigator 1 Incyte Corporation $1.20 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308789
Principal investigator 1 Incyte Corporation $329.45 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308791
Principal investigator 1 Incyte Corporation $28.16 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308793
Principal investigator 1 Incyte Corporation $140.64 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308795
Principal investigator 1 Incyte Corporation $93.60 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308859
Principal investigator 1 Incyte Corporation $76.40 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308861
Principal investigator 1 Incyte Corporation $93.60 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308863
Principal investigator 1 Incyte Corporation $93.60 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308865
Principal investigator 1 Incyte Corporation $76.40 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308867
Principal investigator 1 Incyte Corporation $188.00 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308869
Principal investigator 1 Incyte Corporation $188.00 05/08/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744308871
Principal investigator 1 Incyte Corporation $15.40 05/06/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors No dispute reported 06/30/2026 744311245
Principal investigator 1 Incyte Corporation $15.40 05/06/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors No dispute reported 06/30/2026 744311247
Principal investigator 1 Incyte Corporation $15.40 05/06/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors No dispute reported 06/30/2026 744311249
Principal investigator 1 Incyte Corporation $15.40 05/06/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors No dispute reported 06/30/2026 744311251
Principal investigator 1 Incyte Corporation $15.40 05/06/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors No dispute reported 06/30/2026 744311253
Principal investigator 1 Incyte Corporation $15.40 05/06/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors No dispute reported 06/30/2026 744311255
Principal investigator 1 Incyte Corporation $95.00 05/01/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744296123
Principal investigator 1 EMD Serono, Inc. $61.00 04/30/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749587057
Principal investigator 1 Merck Sharp & Dohme Corporation $319,871.02 04/17/2020 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Phase II Study for the Evaluation of Efficacy of Pembrolizumab MK-3475 in Patients with Advanced Types of Cancers No dispute reported 06/30/2026 740703937
Principal investigator 1 Incyte Corporation $95.00 04/01/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744296121
Principal investigator 1 EMD Serono, Inc. $61.00 03/31/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749586985
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,658.09 03/25/2020 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 PD 1, AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 724449691
Principal investigator 1 Incyte Corporation $41,434.20 03/24/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744273755
Principal investigator 1 EMD Serono, Inc. $901.00 03/12/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749609715
Principal investigator 1 EMD Serono, Inc. $1,802.00 03/12/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749609719
Principal investigator 1 Incyte Corporation $39,000.00 03/05/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1,2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage 3B or Stage 4 Non Small Cell Lung Cancer and Stage 4 Microsatellite Stable Colorectal Cancer No dispute reported 06/30/2026 744273739
Principal investigator 1 Incyte Corporation $30,000.00 03/05/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1,2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage 3B or Stage 4 Non Small Cell Lung Cancer and Stage 4 Microsatellite Stable Colorectal Cancer No dispute reported 06/30/2026 744273741
Principal investigator 1 Incyte Corporation $71,447.90 03/05/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1,2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage 3B or Stage 4 Non Small Cell Lung Cancer and Stage 4 Microsatellite Stable Colorectal Cancer No dispute reported 06/30/2026 744273743
Principal investigator 1 Incyte Corporation $1,016.00 03/05/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1,2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage 3B or Stage 4 Non Small Cell Lung Cancer and Stage 4 Microsatellite Stable Colorectal Cancer No dispute reported 06/30/2026 744273745
Principal investigator 1 Incyte Corporation $3,000.00 03/05/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1,2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage 3B or Stage 4 Non Small Cell Lung Cancer and Stage 4 Microsatellite Stable Colorectal Cancer No dispute reported 06/30/2026 744273747
Principal investigator 1 Incyte Corporation $5,000.00 03/05/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1,2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage 3B or Stage 4 Non Small Cell Lung Cancer and Stage 4 Microsatellite Stable Colorectal Cancer No dispute reported 06/30/2026 744273749
Principal investigator 1 Incyte Corporation $3,750.00 03/05/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1,2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage 3B or Stage 4 Non Small Cell Lung Cancer and Stage 4 Microsatellite Stable Colorectal Cancer No dispute reported 06/30/2026 744273751
Principal investigator 1 Incyte Corporation $9,100.00 03/05/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1,2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage 3B or Stage 4 Non Small Cell Lung Cancer and Stage 4 Microsatellite Stable Colorectal Cancer No dispute reported 06/30/2026 744273753
Principal investigator 1 Incyte Corporation $18,538.20 03/03/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744273737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,849.80 03/02/2020 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 PD 1, AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 724449665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 03/02/2020 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 PD 1, AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 724449671
Principal investigator 1 Incyte Corporation $95.00 03/01/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744296073
Principal investigator 1 EMD Serono, Inc. $61.00 02/28/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749586979
Principal investigator 1 Incyte Corporation $210.00 02/11/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors No dispute reported 06/30/2026 744311221
Principal investigator 1 Incyte Corporation $210.00 02/11/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors No dispute reported 06/30/2026 744311223
Principal investigator 1 Incyte Corporation $210.00 02/11/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors No dispute reported 06/30/2026 744311225
Principal investigator 1 Incyte Corporation $210.00 02/11/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors No dispute reported 06/30/2026 744311227
Principal investigator 1 Incyte Corporation $210.00 02/11/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors No dispute reported 06/30/2026 744311229
Principal investigator 1 Incyte Corporation $210.00 02/11/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors No dispute reported 06/30/2026 744311231
Principal investigator 1 Incyte Corporation $210.00 02/11/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors No dispute reported 06/30/2026 744311233
Principal investigator 1 Incyte Corporation $210.00 02/11/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors No dispute reported 06/30/2026 744311235
Principal investigator 1 Incyte Corporation $210.00 02/11/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors No dispute reported 06/30/2026 744311237
Principal investigator 1 Incyte Corporation $210.00 02/11/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors No dispute reported 06/30/2026 744311239
Principal investigator 1 Incyte Corporation $210.00 02/11/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors No dispute reported 06/30/2026 744311241
Principal investigator 1 Incyte Corporation $210.00 02/11/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors No dispute reported 06/30/2026 744311243
Principal investigator 1 Merck Sharp & Dohme Corporation $203,484.00 02/04/2020 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Phase II Study for the Evaluation of Efficacy of Pembrolizumab MK-3475 in Patients with Advanced Types of Cancers No dispute reported 06/30/2026 740703935
Principal investigator 1 Incyte Corporation $95.00 02/01/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744296071
Principal investigator 1 EMD Serono, Inc. $61.00 01/31/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749586975
Recipient Novartis Pharmaceuticals Corporation $219.00 01/30/2020 Covered Recipient Physician RESEARCH RELATED PUBLICATIONS SUPPORT No dispute reported 06/30/2026 721486187
Recipient Novartis Pharmaceuticals Corporation $285.00 01/30/2020 Covered Recipient Physician RESEARCH RELATED PUBLICATIONS SUPPORT No dispute reported 06/30/2026 721486189
Recipient Regeneron Pharmaceuticals, Inc. $1,087.29 01/22/2020 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 724434931
Principal investigator 1 Novartis Pharmaceuticals Corporation $45,414.02 01/13/2020 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE I THROUGH IB AND OR II OPEN LABEL MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF MBG453 AS SINGLE AGENT AND IN COMBINATION WITH PDR001 IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 721488935
Principal investigator 1 Incyte Corporation $43,734.60 01/07/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744273733
Principal investigator 1 Incyte Corporation $95.00 01/01/2020 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 744296069